Home Cellular science Mosaic Biosciences Secures Funding from Telegraph Hill Partners to Support Commercial Growth and Expand Drug Discovery Capabilities and Services

Mosaic Biosciences Secures Funding from Telegraph Hill Partners to Support Commercial Growth and Expand Drug Discovery Capabilities and Services

0

BOULDER, Colorado–(BUSINESS WIRE)–Mosaic Biosciences (“Mosaic” or “the Company”), a protein and antibody discovery company that helps partners identify next-generation therapies for the prevention and treatment of disease. announced the closing of an $11.4 million financing led by Telegraph Hill Partners (“THP”), a San Francisco, California-based life science venture and growth capital firm. Dan Mitchell, a Boulder-based venture capitalist, also participated in the financing.

Mosaic provides its partners with experienced leadership and biopharmaceutical research teams to drive the discovery and development of therapeutic proteins, from concept to preclinical development. The Company is working with its partners to expand their research capabilities and accelerate their development programs. Mosaic’s capabilities streamline protein and antibody therapeutic programs, reduce time and cost, and successfully advance programs through the achievement of key discoveries and early development milestones.

The growth funding will be used to expand lab facility infrastructure, develop new technologies and capabilities, strengthen the business development team, and expand Mosaic’s science team to meet changing discovery services needs. protein and antibody therapeutics.

“We are thrilled to partner with the THP team as we work to build the preeminent company for therapeutic protein and antibody discovery,” said Marty Stanton, CEO and COO of Mosaic Biosciences. “We are committed to providing a broad spectrum of discovery capabilities to help our partners bring transformative therapies to their patients.”

“Mosaic brings CSO-caliber expertise and experienced biopharmaceutical research teams to design, guide, execute and manage drug programs for their partners that focus on the discovery of innovative drugs,” said Jeanette Welsh, Partner at Telegraph Hill. Partners. “We look forward to working with the full team at Mosaic to address the critical need to solve challenging problems in therapeutic discovery.” Jeanette Welsh and Rob Capone of Telegraph Hill Partners will join Mosaic’s board alongside the financing, and Deval Lashkari of Telegraph Hill Partners will join the board as an observer. Dan Mitchell and Eric Furfine, Mosaic’s CEO and Scientific Director, will also serve on Mosaic’s Board of Directors.

About Mosaic Biosciences:

Mosaic is a protein and antibody discovery company that helps partners identify next-generation therapies for disease prevention and treatment. Mosaic teams provide comprehensive, end-to-end discovery services, including program evaluation and strategy development; program management; antibody discovery and optimization; production, purification and characterization of proteins; protein engineering; development of biochemical and cellular assays; formulation, stability and developability studies; development of bioanalytical assays (PK and PD); and validation pharmacology of clinical candidates. Mosaic’s partners include biopharmaceutical companies, start-ups, and academic venture and seed funds. For more information, please visit www.mosaicbio.com.

About Telegraph Hill Partners:

Telegraph Hill Partners, founded in 2001 and based in San Francisco, Calif., invests in commercial life sciences, medical technology and healthcare companies. For more information, please see www.telegraphhillpartners.com.